English   español  
Please use this identifier to cite or link to this item: http://hdl.handle.net/10261/49810
logo share SHARE logo core CORE   Add this article to your Mendeley library MendeleyBASE

Visualizar otros formatos: MARC | Dublin Core | RDF | ORE | MODS | METS | DIDL
Exportar a otros formatos:
DC FieldValueLanguage
dc.contributor.authorRueda, Noemí-
dc.contributor.authorLlorens-Martín, M.-
dc.contributor.authorFlórez, Jesús-
dc.contributor.authorValdizán, Elsa M.-
dc.contributor.authorBanerjee, Pradeep-
dc.contributor.authorTrejo, José L.-
dc.contributor.authorMartínez-Cué, Carmen-
dc.identifier.citationJournal of Alzheimer's Disease 21(1): 277-290 (2019)es_ES
dc.description.abstractTs65Dn (TS) mice exhibit several phenotypic characteristics of human Down syndrome, including an increased brain expression of amyloid-β protein precursor (AβPP) and cognitive disturbances. Aberrant N-methyl-D-aspartate (NMDA) receptor signaling has been suspected in TS mice, due to an impaired generation of hippocampal long-term potentiation (LTP). Memantine, an uncompetitive NMDA receptor antagonist approved for the treatment of moderate to severe Alzheimer's disease, is known to normalize LTP and improve cognition in transgenic mice with high brain levels of AβPP and amyloid-β protein. It has recently been demonstrated that acute injections of memantine rescue performance deficits of TS mice on a fear conditioning test. Here we show that oral treatment of aged TS mice with a clinically relevant dose of memantine (30 mg/kg/day for 9 weeks) improved spatial learning in the water maze task and slightly reduced brain AβPP levels. We also found that TS mice exhibited a significantly reduced granule cell count and vesicular glutamate transporter-1 (VGLUT1) labeling compared to disomic control mice. After memantine treatment, the levels of hippocampal VGLUT1 were significantly increased, reaching the levels observed in vehicle treated-control animals. Memantine did not significantly affect granule cell density. These data indicate that memantine may normalize several phenotypic abnormalities in TS mice, many of which – such as impaired cognition – are also associated with Down syndrome and Alzheimer's disease.es_ES
dc.publisherIOS Presses_ES
dc.subjectAlzheimer's diseasees_ES
dc.subjectAmyloid-β protein precursores_ES
dc.titleMemantine normalizes several phenotypic features in the Ts65Dn mouse model of Down syndromees_ES
dc.description.peerreviewedPeer reviewedes_ES
Appears in Collections:(IBBTEC) Artículos
(IC) Artículos
Files in This Item:
File Description SizeFormat 
accesoRestringido.pdf15,38 kBAdobe PDFThumbnail
Show simple item record

Related articles:

WARNING: Items in Digital.CSIC are protected by copyright, with all rights reserved, unless otherwise indicated.